The ABPI is proud to announce the appointment of Richard Torbett, who will be taking up the role of Executive Director – Commercial UK at the end of July.
Richard will be responsible for heading up the Association’s commercial strategy and leading the UK commercial team. His main focus will be on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in the UK. He will be working closely with the NHS on all aspects of medicines use, procurement and distribution and supply, and will report to the ABPI’s CEO.
Before joining the ABPI, Richard held the prestigious role of Chief Economist and Director of Strategy at the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he was also responsible for building trusted partnerships with international economic institutions. Prior to this, Richard spent six years working at Pfizer, where he was Senior Director and Head of International Affairs.
Richard has a strong track record in health policy and has been a vocal commentator on debates around future healthcare, innovation and the role of pharmaceuticals. Furthermore, he has extensive experience of working in government, having previously held a number of roles as part of the UK government’s economic service as well as at the European Commission.
Welcoming Richard’s appointment, Alison Clough, ABPI Acting CEO, said: “With his wealth of knowledge and expertise, Richard will be very well placed to direct the ABPI’s commercial strategy and to lead the UK commercial team. His experience in both government and the pharmaceutical industry will prove invaluable when addressing the issues of access and use of new medicines in the NHS and in leading discussions with the Department of Health around the PPRS. He will be a great addition to the ABPI and we very much look forward to welcoming him at the end of July.”
Commenting on his appointment, Richard said: “I am absolutely delighted to be joining the ABPI. The UK is at the forefront of discovery and innovation and I welcome the chance to join at such an exciting time for the life sciences industry.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com